The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Primary Prevention of Cardiovascular Disease in Diabetes Mellitus
Open accessAbstract
Type 2 diabetes mellitus (T2D) is a major risk factor for cardiovascular disease (CVD), the most common cause of death in T2D. Yet, <50% of U.S. adults with T2D meet recommended guidelines for CVD prevention. The burden of T2D is increasing: by 2050, approximately 1 in 3 U.S. individuals may have T2D, and patients with T2D will comprise an increasingly large proportion of the CVD population. The authors believe it is imperative that we expand the use of therapies proven to reduce CVD risk in patients with T2D. The authors summarize evidence and guidelines for lifestyle (exercise, nutrition, and weight management) and CVD risk factor (blood pressure, cholesterol and blood lipids, glycemic control, and the use of aspirin) management for the prevention of CVD among patients with T2D. The authors believe appropriate lifestyle and CVD risk factor management has the potential to significantly reduce the burden of CVD among patients with T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Instead, evidence to support lifestyle and health behavior management for T2DM and stable CAD has been extrapolated from primary prevention trials and from subgroups of participants with T2DM from studies focusing on the secondary prevention of CAD.63,136”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [136]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet
Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1200303 · Cited by 4,257
RetractedEstruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1806491 · Cited by 1,008
Retracted(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 4×
“The Look-AHEAD trial, the Steno-2 study, and the DPP all combined different lifestyle parameters, including weight loss, physical activity and exercise, and a dietary intervention (5,7,9).”
BackgroundMethodInfluentialEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2014) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,609
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Standards of Medical Care in Diabetes
Power, D. V. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,676
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“In particular, a sodium glucose cotransporter-2 (SGLT2) inhibitor (empagliflozin) and glucagon-like peptide (GLP)-1 analogues (liraglutide and semaglutide), have recently demonstrated a reduction in mortality (67,68) and CVD events (67–69) among patients with diabetes and preexisting CVD or multiple CVD risk factors.”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Sacks, F. M., Svetkey, L. P., Vollmer, W. M., Appel, L. J., Bray, G. A., Harsha, D., Obarzanek, E., Conlin, P. R., Miller, E. R., Simons-Morton, D. G., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101043440101 · Cited by 5,638
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 4,803
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Adler, A. I. (2000) · BMJ · doi:10.1136/bmj.321.7258.412 · Cited by 2,133
(2000) · PubMed · Cited by 2,095
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F. L., Powe, N. R., & Golden, S. H. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00007 · Cited by 1,657
Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560
The J-Curve Phenomenon in Hypertension
Kang, Y., & Wang, J. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,551
Kinaan, M., Ding, H., & Triggle, C. R. (2015) · Medical Principles and Practice · doi:10.1159/000381643 · Cited by 1,515
Clinical Update: Cardiovascular Disease in Diabetes Mellitus
Wang, C. C. L., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,222
Estacio, R. O., Jeffers, B. W., Hiatt, W. R., Biggerstaff, S. L., Gifford, N., & Schrier, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803053381003 · Cited by 1,151
Gæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981
Xie, X., Atkins, E., Lv, J., Bennett, A., Neal, B., Ninomiya, T., Woodward, M., MacMahon, S., Turnbull, F., Hillis, G. S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00805-3 · Cited by 980
Achievement of Goals in U.S. Diabetes Care, 1999–2010
Ali, M. K., Bullard, K. M., Saaddine, J. B., Cowie, C. C., Imperatore, G., & Gregg, E. W. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1213829 · Cited by 979
Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., Lee, R., Bancroft, J., MacEwan, S., Shepherd, J., et al. (2008) · BMJ · doi:10.1136/bmj.a1840 · Cited by 977
Church, T. S., Blair, S. N., Cocreham, S., Johannsen, N., Johnson, W., Kramer, K., Mikus, C. R., Myers, V., Nauta, M., Rodarte, R. Q., et al. (2010) · JAMA · doi:10.1001/jama.2010.1710 · Cited by 944
Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Diabetes Care · doi:10.2337/dc08-9026 · Cited by 881
Blood Pressure Lowering in Type 2 Diabetes: A Systematic Review and Meta-analysis
Emdin, C. A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., & Patel, A. (2015) · JAMA · doi:10.1001/jama.2014.18574 · Cited by 854
Schrier, R. W., Estacio, R. O., Esler, A. L., & Mehler, P. S. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00213.x · Cited by 837
Lv, J., Neal, B. C., Ehteshami, P., Ninomiya, T., Woodward, M., Rodgers, A., Wang, H., MacMahon, S. W., Turnbull, F., Hillis, G. S., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001293 · Cited by 777
(2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.193 · Cited by 653
Prevention of Diabetes With Mediterranean Diets: A Subgroup Analysis of a Randomized Trial
Salas-Salvadó, J., Bulló, M., Estruch, R., Ros, E., Covas, M.-I., Ibarrola-Jurado, N., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1725 · Cited by 650
Knopp, R. H., d’Emden, M., Smilde, J. G., Pocock, S. J., & on behalf of the ASPEN Study Group (2006) · Diabetes Care · doi:10.2337/dc05-2415 · Cited by 550
Shepherd, J., Barter, P., Carmena, R., Deedwania, P., Fruchart, J.-C., Haffner, S., Hsia, J., Breazna, A., LaRosa, J., Grundy, S., et al. (2006) · Diabetes Care · doi:10.2337/dc05-2465 · Cited by 525
Type 1 Diabetes Mellitus and Cardiovascular Disease
de Ferranti, S. D., de Boer, I. H., Fonseca, V. A., Fox, C. S., Golden, S. H., Lavie, C. J., Magge, S. N., Marx, N., McGuire, D. K., Orchard, T. J., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000034 · Cited by 516
A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses
Esposito, K., Maiorino, M. I., Bellastella, G., Chiodini, P., Panagiotakos, D., & Giugliano, D. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008222 · Cited by 501
Aspirin Effects on Mortality and Morbidity in Patients With Diabetes Mellitus
Kassoff, A. (1992) · JAMA · doi:10.1001/jama.1992.03490100090033 · Cited by 479
Skyler, J. S., Bergenstal, R. M., Bonow, R. O., Buse, J. B., DEEDWANIA, P. C., Gale, E. A., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P. D., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.008 · Cited by 473
Griffin, S. J., Borch-Johnsen, K., Davies, M. J., Khunti, K., Rutten, G. E., Sandbæk, A., Sharp, S. J., Simmons, R. K., van den Donk, M., Wareham, N. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60698-3 · Cited by 462
de Ferranti, S. D., de Boer, I. H., Fonseca, V. A., Fox, C. S., Golden, S. H., Lavie, C. J., Magge, S. N., Marx, N., McGuire, D. K., Orchard, T. J., et al. (2014) · Diabetes Care · doi:10.2337/dc14-1720 · Cited by 444
Riddle, M. C., Ambrosius, W. T., Brillon, D. J., Buse, J. B., Byington, R. P., Cohen, R. M., Goff, D. C., Malozowski, S., Margolis, K. L., Probstfield, J. L., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1278 · Cited by 406
De Berardis, G., Sacco, M., Strippoli, G. F. M., Pellegrini, F., Graziano, G., Tognoni, G., & Nicolucci, A. (2009) · BMJ · doi:10.1136/bmj.b4531 · Cited by 395
Fox, C. S., Golden, S. H., Anderson, C., Bray, G. A., Burke, L. E., de Boer, I. H., Deedwania, P., Eckel, R. H., Ershow, A. G., Fradkin, J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000230 · Cited by 386
Brunström, M., & Carlberg, B. (2016) · BMJ · doi:10.1136/bmj.i717 · Cited by 375
Skyler, J. S., Bergenstal, R. M., Bonow, R. O., Buse, J. B., DEEDWANIA, P. C., Gale, E. A., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P. D., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.191305 · Cited by 346
Effects of Exercise on Cardiovascular Risk Factors in Type 2 Diabetes
Chudyk, A., & Petrella, R. J. (2011) · Diabetes Care · doi:10.2337/dc10-1881 · Cited by 331
Balducci, S. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.380 · Cited by 329
Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes
Pignone, M. P., Alberts, M. J., Colwell, J. A., Cushman, M., Inzucchi, S. E., Mukherjee, D., Rosenson, R. S., Williams, C. D., Wilson, P. W. F., & Kirkman, M. S. (2010) · Diabetes Care · doi:10.2337/dc10-0555 · Cited by 269
Clair, C., Rigotti, N. A., Porneala, B., Fox, C. S., D’Agostino, R. B., Pencina, M. J., & Meigs, J. B. (2013) · JAMA · doi:10.1001/jama.2013.1644 · Cited by 255
Sacks, F. M., Carey, V. J., Anderson, C. A. M., Miller, E. R., Copeland, T., Charleston, J., Harshfield, B. J., Laranjo, N., McCarron, P., Swain, J., et al. (2014) · JAMA · doi:10.1001/jama.2014.16658 · Cited by 239
The Diabetes Prevention Program Outcomes Study Research Group; prepared on behalf of the DPPOS Research Group, Orchard, T. J., Temprosa, M., Barrett‐Connor, E., Fowler, S. E., Goldberg, R. B., Mather, K. J., Marcovina, S. M., Montez, M., Ratner, R. E., et al. (2013) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03750.x · Cited by 214
Treatment blood pressure targets for hypertension
Arguedas, J. A., Perez, M. I., & Wright, J. M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004349.pub2 · Cited by 207
Redefining Blood-Pressure Targets — SPRINT Starts the Marathon
Perkovic, V., & Rodgers, A. (2015) · New England Journal of Medicine · doi:10.1056/nejme1513301 · Cited by 136
Daly, C., Fox, K. M., Remme, W. J., Bertrand, M. E., Ferrari, R., & Simoons, M. L. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi225 · Cited by 131
McBrien, K., Rabi, D. M., Campbell, N., Barnieh, L., Clement, F., Hemmelgarn, B. R., Tonelli, M., Leiter, L. A., Klarenbach, S. W., & Manns, B. J. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.3147 · Cited by 129
Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes
Pignone, M. P., Alberts, M. J., Colwell, J. A., Cushman, M., Inzucchi, S. E., Mukherjee, D., Rosenson, R. S., Williams, C. D., Wilson, P. W. F., & Kirkman, M. S. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.04.003 · Cited by 103
Estacio, R., Coll, J. R., Tran, Z. V., & Schrier, R. W. (2006) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2006.05.011 · Cited by 98
Aspirin for the Primary Prevention of Cardiovascular Events
Calvin, A. D., Aggarwal, N. R., Murad, M. H., Shi, Q., Elamin, M. B., Geske, J. B., Fernández-Balsells, M., Albuquerque, F. N., Lampropulos, J. F., Erwin, P. J., et al. (2009) · Diabetes Care · doi:10.2337/dc09-1297 · Cited by 98
Susceptibility of LDL and its subfractions to glycation
Soran, H., & Durrington, P. N. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328348a43f · Cited by 91
The Potential for Postrandomization Confounding in Randomized Clinical Trials
Manson, J. E., SHUFELT, C. L., & Robins, J. M. (2016) · JAMA · doi:10.1001/jama.2016.3676 · Cited by 54
The Consult Guys - Atrial Fibrillation: How Controlled Is Well-Controlled?
Merli, G. J., & Weitz, H. H. (2014) · Annals of Internal Medicine · doi:10.7326/g14-3001 · Cited by 42
Multifactorial Intervention to Reduce Cardiovascular Events in Type 2 Diabetes
Rajpathak, S. N., Aggarwal, V., & Hu, F. B. (2010) · Current Diabetes Reports · doi:10.1007/s11892-009-0084-8 · Cited by 18
Cited by
Sorted by citations
Role of the gut microbiota in type 2 diabetes and related diseases
Yang, G., Wei, J., Liu, P., Zhang, Q., Tian, Y., Hou, G., Meng, L., Xin, Y., & Jiang, X. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154712 · Cited by 418
Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy
Marwick, T. H., Ritchie, R., Shaw, J. E., & Kaye, D. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.019 · Cited by 365
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Self-citationDiabetes mellitus—Progress and opportunities in the evolving epidemic
Abel, E. D., Gloyn, A. L., Evans‐Molina, C., Joseph, J. J., Misra, S., Pajvani, U. B., Simcox, J., Suszták, K., & Drucker, D. J. (2024) · Cell · doi:10.1016/j.cell.2024.06.029 · Cited by 350
The effects of physical exercise on fatty liver disease.
van der Windt, D. J., Sud, V., Zhang, H., Tsung, A., & Huang, H. (2018) · Gene Expression · doi:10.3727/105221617x15124844266408 · Cited by 294
Metadata
- Authors
- Newman, J. D., Schwartzbard, A. Z., Weintraub, H. S., Goldberg, I. J., & Berger, J. S.
- Affiliations
- NYU Langone Health (US)
- Corresponding author
- Newman, Jonathan D.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 70
- Issue
- 7
- Pages
- 883-893
- ISSN
- 0735-1097 (ISSN-L)
- PMC
- PMC5656394
- OpenAlex
- W2744536672
- Cited by
- 205
- References
- 89
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 28 · 2023: 22 · 2022: 57 · 2021: 18 · 2020: 21 · 2019: 14 · 2018: 20 · 2017: 2
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- American Heart Association (15MCPRP24480132)
- Amgen
- AstraZeneca
- Sanofi
- Gilead Sciences
- Amarin Corporation
- National Institutes of Health (HL114978)
- National Heart, Lung, and Blood Institute (P01HL092969, K23HL125991, HL-114978, R01HL114978)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Keywords
- type 2 diabetes, cardiovascular disease prevention, primary prevention, lifestyle modification, physical activity, nutrition, weight management, blood pressure control, glycemic control, aspirin therapy, cardiovascular risk factors
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Morbidity, Primary Prevention, Risk Factors, Global Health
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
